

ESOU21

18th Meeting of
the EAU Section of
Oncological Urology

29-31 January 2021

www.esou21.org

Virtual
meeting

Friday 29 January 2021

08:00 - 09:05	Prostate cancer I: Diagnosis and staging <i>Chairs</i> A. De La Taille, Créteil (FR) G. Giannarini, Udine (IT)
08:00 - 08:05	Welcome M. Rouprêt, Paris (FR)
08:05 - 08:35	Clinical case discussion Should systematic biopsy always be performed in adjunct to MRI-targeted biopsy?
08:05 - 08:10	Clinical case presentation A. Stabile, Milan (IT)
08:10 - 08:20	Yes G. Ploussard, Toulouse (FR)
08:20 - 08:30	No C. Moore, London (GB)
08:30 - 08:35	Discussion
08:35 - 09:05	Clinical case discussion PSMA PET, not conventional imaging, should be performed for primary staging of high-risk prostate cancer
08:35 - 08:40	Clinical case presentation S.R. Da Silva Gaspar, Lisbon (PT)
08:40 - 08:50	Pro F. Ceci, Torino (IT)
08:50 - 09:00	Con H.G. Van Der Poel, Amsterdam (NL)
09:00 - 09:05	Discussion
09:05 - 09:20	Break
09:20 - 10:10	Renal cancer I: Localised <i>Chairs</i> A. Alcaraz, Barcelona (ES) A. Volpe, Novara (IT)
09:20 - 09:40	Surgery in detail - Key points on partial nephrectomy
09:20 - 09:26	Preparation of renal hilum - Use of fluorescence A. Volpe, Novara (IT)
09:26 - 09:33	Ischemia vs. no ischemia A. Mottrie, Aalst (BE)
09:33 - 09:40	Resection techniques C.K. Bensalah, Rennes (FR)
09:40 - 10:10	Clinical case discussion RCC > 7cm: How to deal with it?
09:40 - 09:45	Clinical case presentation M.C. Mir Maresma, Valencia (ES)
09:45 - 09:55	Radical surgery M-O. Grimm, Jena (DE)
09:55 - 10:05	Nephron sparing surgery A. Minervini, Florence (IT)
10:05 - 10:10	Discussion

10:10 - 11:00	Urothelial and bladder cancer I: Conservative management of urothelial cancer - UTUC and BC <i>Chairs</i> L-M. Krabbe, Münster (DE) M. Rouprêt, Paris (FR)
10:10 - 10:20	How to improve the diagnosis assessment? A. Breda, Barcelona (ES)
10:20 - 10:30	Biomarkers in the diagnosis and follow-up of bladder cancer in 2021: Where do we stand? E. Xylinas, Paris (FR)
10:30 - 10:40	Alternative treatments for refractory to BCG NMIBC M. Babjuk, Prague (CZ)
10:40 - 11:00	Clinical case discussion En-bloc vs. TURB
10:40 - 10:45	Clinical case presentation I. Vela, Woolloongabba (AU)
10:45 - 11:00	Panel discussion <i>Panel</i> M. Babjuk, Prague (CZ) B. Malavaud, Toulouse (FR) O. Rodriguez Faba, Barcelona (ES)
11:00 - 11:15	Break
11:15 - 12:05	Rare tumours: Minimising impact and maximising quality of life of penile and testis cancer <i>Chairs</i> P. Albers, Düsseldorf (DE) M. Albersen, Leuven (BE)
11:15 - 11:18	Introduction P. Albers, Düsseldorf (DE) M. Albersen, Leuven (BE)
11:18 - 11:28	eUROGEN lecture Reducing morbidity and complications by knowledge sharing in rare tumours V. Sangar, Manchester (GB)
11:28 - 11:38	Reducing morbidity of inguinal lymph node staging; new developments in ILND and sentinel node biopsy O.R. Brouwer, Amsterdam (NL)
11:38 - 11:50	Personalised therapy to reduce treatment morbidity in testicular cancer P. Albers, Düsseldorf (DE)
11:50 - 12:00	Fertility preservation in testis cancer patients J. Van Damme, Piétrebais (BE)
12:00 - 12:05	Discussion and take home message
13:05 - 14:05	Prostate cancer II: Localised disease <i>Chairs</i> A. Heidenreich, Cologne (DE) J.P.M. Sedelaar, Nijmegen (NL)
13:05 - 13:35	Clinical case discussion Improving risk stratification in men with intermediate-risk prostate cancer to optimise treatment
13:05 - 13:10	Clinical case presentation I. Heidegger, Innsbruck (AT)
13:10 - 13:20	Active surveillance R.C.N. Van Den Bergh, Nieuwegein (NL)
13:20 - 13:30	Active treatment F.C. Hamdy, Oxford (GB)
13:30 - 13:35	Discussion

Scientific Programme - ESOU21 Virtual

13:35 - 14:05	Clinical case discussion Will pelvic lymph node dissection at the time of radical prostatectomy change in the PSMA-PET era?
13:35 - 13:40	Clinical case presentation A. Ingels, Paris (FR)
13:40 - 13:50	Yes C.G. Eden, Guildford (GB)
13:50 - 14:00	No A. Briganti, Milan (IT)
14:00 - 14:05	Discussion

Saturday 30 January 2021

10:00 - 11:00	Prostate cancer III: Locally advanced and oligometastatic prostate cancer <i>Chairs</i> S. Joniau, Leuven (BE) F. Montorsi, Milan (IT)
10:00 - 10:30	Clinical case discussion Adjuvant or salvage radiation therapy after radical prostatectomy for high-risk prostate cancer?
10:00 - 10:05	Clinical case presentation G. Gandaglia, Milan (IT)
10:05 - 10:30	Panel discussion <i>Panel</i> A. Bossi, Villejuif (FR) A. Briganti, Milan (IT) A. Heidenreich, Cologne (DE)
10:30 - 11:00	Clinical case discussion Optimal treatment of men with cM1a prostate cancer in the PSMA PET era
10:30 - 10:35	Clinical case presentation G. Gandaglia, Milan (IT)
10:35 - 11:00	Panel discussion <i>Panel</i> N. James, London (GB) S. Joniau, Leuven (BE) T. Zilli, Genève (CH)
11:15 - 12:05	Urothelial cancer II <i>Chairs</i> P.L. Chlosta, Cracow (PL) E. Xylinas, Paris (FR)
11:15 - 11:18	Introduction P.L. Chlosta, Cracow (PL) E. Xylinas, Paris (FR)
11:18 - 11:28	Neoadjuvant vs. adjuvant chemotherapy/immunotherapy in high-risk UTUC: Indications and controversies A. Necchi, Milan (IT)
11:28 - 11:38	Open or robotic nephroureterectomy for high-risk UTUC? S. Shariat, Vienna (AT)
11:38 - 11:48	Re-TUR in Ta High-Grade for selected candidates M. Moschini, Lucerne (CH)
11:48 - 11:58	Tri-modal vs. bi-modal vs. TURBT alone as an alternative to radical cystectomy N. James, London (GB)
11:58 - 12:05	Discussion and take home message
12:05 - 12:55	Joint session ESOU and European Urology Oncology (EUO): Renal cancer II - locally advanced and metastatic <i>Chairs</i> L. Albiges, Villejuif (FR) M-O. Grimm, Jena (DE)
12:05 - 12:07	Introduction L. Albiges, Villejuif (FR) M-O. Grimm, Jena (DE)
12:07 - 12:22	EUO lecture Systemic treatment of metastatic RCC T. Powles, London (GB)
12:22 - 12:32	Surgical and perioperative challenges of the large renal tumours (vena cava and lymph node involvement) A. Mejean, Paris (FR)
12:32 - 12:55	Clinical case discussion Perioperative care of geriatric RCC patients

12:32 - 12:37	Clinical case presentation U. Capitanio, Milan (IT)
12:37 - 12:55	Panel discussion <i>Panel</i> M-O. Grimm, Jena (DE) A. Mejean, Paris (FR) L. Albiges, Villejuif (FR)
12:55 - 13:55	Setting the scene: Impact of COVID-19 on cancer treatment <i>Chairs</i> R.C.N. Van Den Bergh, Nieuwegein (NL) M.C. Mir Maresma, Valencia (ES) Learning objectives In this educational session a multidisciplinary panel of experts from different medical specialties will discuss the impact COVID-19 and assess the pros and cons of new developments that were spurred by the restrictions as a result of the pandemic. Also experiences from a patient perspective will be addressed and discussed amongst the panelist. This interactive session will include polling features to better understand the clinical and patient needs in the treatment of urological cancers.
12:55 - 13:15	Setting the scene: Impact of COVID-19 on cancer treatment
12:55 - 13:00	Risks from deferring treatment for urological cancers: How to aid management during the COVID-19 pandemic L. Lenfant, Paris (FR)
13:00 - 13:05	Impact of COVID-19 outbreak on oncological robotic-assisted surgeries: Risk assessment of the pandemic A. Ingels, Paris (FR)
13:05 - 13:10	EAU Guidelines Office Rapid Reaction Group: Adapted guidelines recommendations to the coronavirus disease 2019 era M.J. Ribal Caparros, Barcelona (ES)
13:10 - 13:15	Polling results and discussion
13:15 - 13:35	Telemedicine during the COVID-19 Pandemic
13:15 - 13:20	Virtual Tumour Board: Pros and cons from physician's perspective R. Campi, Florence (IT)
13:20 - 13:25	The positive environmental impact of remote teleconsultation in urology at the time of the COVID-19 pandemic in a highly populated area: A prospective study U. Pinar, Paris (FR)
13:25 - 13:30	Preliminary assessment of patient and physician satisfaction with the use of teleconsultation in urology during the COVID-19 pandemic J. Gómez Rivas, Madrid (ES)
13:30 - 13:35	Polling results and discussion
13:35 - 13:55	A cancer patient's journey during COVID-19
13:35 - 13:40	Access to consultation and treatment D. Fisher, Seaford (GB)
13:40 - 13:45	Quality of life complications D. Fisher, Seaford (GB)
13:45 - 13:50	Psychological aspect post-pandemic N.R. Bhatt, Cambridge (GB)
13:50 - 13:55	Polling results and discussion

13:55 - 14:55

ESU-ESOU-ERUS

Chairs

A. Breda, Barcelona (ES)

M. Rouprêt, Paris (FR)

J. Palou, Barcelona (ES)

13:55 - 13:58

Introduction

A. Breda, Barcelona (ES)

M. Rouprêt, Paris (FR)

J. Palou, Barcelona (ES)

13:58 - 14:11

Teaching robotic surgery: Yesterday, today and tomorrow

A. Mottrie, Melle (BE)

14:11 - 14:24

Which tumours should not be operated with a robot?

J. Palou, Barcelona (ES)

14:24 - 14:37

RPN and its variants

A. Minervini, Florence (IT)

14:37 - 14:50

Robotic surgery at its best

A. Breda, Barcelona (ES)

14:50 - 14:55

Questions and take home message

14:55 - 15:10

Break

15:10 - 16:00

Prostate cancer IV: Oligometastatic prostate cancer

Chairs

A. Bossi, Villejuif (FR)

N. Mottet, Saint-Étienne (FR)

15:10 - 15:20

EAU Section of Urological Research (ESUR) lecture Genetic testing for prostate cancer: When and how?

K. Knudsen, Philadelphia (US)

15:20 - 15:30

The future of stereotactic body radiation therapy in prostate cancer

G. De Meerleer, Leuven (BE)

15:30 - 16:00

Clinical case discussion Oligometastatic nodal and bony recurrence after radiation therapy

15:30 - 15:35

Clinical case presentation

F. Preisser, Frankfurt (DE)

15:35 - 16:00

Panel discussion

Panel

S. Gillessen Sommer, Bellinzona (CH)

B.A. Hadaschik, Essen (DE)

P. Ost, Ghent (BE)

J. Walz, Marseille (FR)

16:00 - 18:00

STEPS (Session To Evaluate Progress) programme

Chair

M. Rouprêt, Paris (FR)

Learning objectives

STEPS offers younger, recently specialised clinicians the opportunity to interact directly with high-level onco-urology experts and ESOU Board members to discuss clinical scenarios and develop their treatment decision-making skills.

16:00 - 16:05

Introduction

M. Rouprêt, Paris (FR)

16:05 - 17:50

Prostate cancer table

Chair

N. Mottet, Saint-Étienne (FR)

S. Joniau, Leuven (BE)

16:05 - 17:50

Bladder cancer table

Chair

G.N. Thalmann, Bern (CH)

E. Xylinas, Paris (FR)

16:05 - 17:50

Renal cancer table

Scientific Programme - ESOU21 Virtual

Chair A. Mejean, Paris (FR)
A. Volpe, Novara (IT)

16:05 - 17:50

Rare (penis and testis) table

Chair P. Albers, Düsseldorf (DE)
M. Albersen, Leuven (BE)

17:50 - 18:00

Conclusion

M. Rouprêt, Paris (FR)

Sunday 31 January 2021

- 10:00 - 10:50** **Video session - Penile and testicular cancer**
Chairs P. Albers, Düsseldorf (DE)
M. Albersen, Leuven (BE)
- 10:00 - 10:03** **Introduction**
P. Albers, Düsseldorf (DE)
M. Albersen, Leuven (BE)
- 10:03 - 10:13** **Glansectomy and glans resurfacing for penile cancer**
B.E. Ayres, London (GB)
- 10:13 - 10:23** **Minimal invasive inguinal lymph node dissection in penile cancer**
A. Parnham, Manchester (GB)
- 10:23 - 10:33** **Partial orchiectomy and oncotese**
M. Dinkelman-Smit, Rotterdam (NL)
- 10:33 - 10:43** **Robotic RPLND in testis cancer**
A. Hiester, Düsseldorf (DE)
- 10:43 - 10:50** **Discussion and take home message**
- 10:50 - 11:50** **Renal cancer III: Advanced and metastatic renal cancer**
Chairs A. Bex, London (GB)
A. Ravaud, Bordeaux (FR)
- 10:50 - 11:00** **Histological classification and immunophenotyping of renal tumours**
H. Moch, Zurich (CH)
- 11:00 - 11:10** **Is cytoreductive nephrectomy still alive? When and why?**
A. Bex, London (GB)
- 11:10 - 11:20** **Does every metastatic patient need immunotherapy in a first-line setting?**
A. Ravaud, Bordeaux (FR)
- 11:20 - 11:50** **Clinical case discussion Advanced and metastatic RCC**
Moderator M-O. Grimm, Jena (DE)
- 11:20 - 11:25** **Clinical case presentation**
C. Thibault, Paris (FR)
- 11:25 - 11:50** **Panel discussion**
Panel L. Albiges, Villejuif (FR)
A. Bex, London (GB)
A. Ravaud, Bordeaux (FR)
- 11:50 - 12:35** **Prostate cancer V: Metastatic disease**
Chairs S. Gillessen Sommer, Bellinzona (CH)
F. Rozet, Paris (FR)
- 11:50 - 12:05** **Society Urological Oncology (SUO) lecture Using biomarkers to guide targeted treatment in advanced prostate cancer**
M. Cookson, Oklahoma City (US)
- 12:05 - 12:35** **Clinical case discussion Metastatic prostate cancer**
- 12:05 - 12:10** **Case 1: Metastatic hormone-naïve prostate cancer: The right drug for the right patient**
C. Thibault, Paris (FR)
- 12:10 - 12:15** **Case 2: Novel therapies in metastatic castration resistant prostate cancer**
P. Gougis, Paris (FR)
- 12:15 - 12:35** **Panel discussion**
-

Panel
S. Gillessen Sommer, Bellinzona (CH)
N. James, London (GB)
B. Tombal, Brussels (BE)
I.M. Van Oort, Nijmegen (NL)

12:35 - 13:50

Joint session of the ESOU, ESUR, ESUP and European Urology Oncology: "Must-read papers in onco-urology 2020"

Chairs
A. Briganti, Milan (IT)
K. Junker, Homburg (DE)
R. Montironi, Ancona (IT)
M. Rouprêt, Paris (FR)

12:35 - 12:45

Prostate cancer
R. Mathieu, Rennes (FR)

12:45 - 12:55

Urothelial cancer
T. Seisen, Paris (FR)

12:55 - 13:05

Renal cancer
R. Campi, Florence (IT)

13:05 - 13:15

Testis and penile cancer
P. Paffenholz, Cologne (DE)

13:15 - 13:30

EAU Section of Urological Research (ESUR) lecture Translational research
K. Junker, Homburg (DE)

13:30 - 13:40

EAU Section of Urothology (ESUP) lecture Bladder neoplasms: Will a morphological classification become obsolete?
A. Lopez-Beltran, Lisbon (PT)

13:40 - 13:50

European Urology Oncology Award Best paper of the year 2021
A. Lalani, Hamilton (CA)

